195,314 Johnson & Johnson $JNJ Shares Acquired by State Street Corp

Johnson & Johnson logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • State Street increased its Johnson & Johnson stake by 195,314 shares, or 0.1%, in the third quarter, bringing its holdings to about 134 million shares worth $35.5 billion.
  • Analysts maintain a “Moderate Buy” consensus, with an average price target of $276.54; recent rating changes included downgrades to Hold and a small reduction in Morgan Stanley’s target.
  • Johnson & Johnson beat quarterly earnings expectations, reporting $2.59 per share and $25.4 billion in revenue, up 5.9% year over year. It also announced a $1.34 quarterly dividend.
  • Five stocks to consider instead of Johnson & Johnson.

State Street Corp boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 0.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 133,971,339 shares of the company's stock after purchasing an additional 195,314 shares during the period. Johnson & Johnson accounts for approximately 1.0% of State Street Corp's holdings, making the stock its 15th largest holding. State Street Corp owned approximately 5.57% of Johnson & Johnson worth $35,467,572,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. CKW Financial Group lifted its position in Johnson & Johnson by 0.9% during the 3rd quarter. CKW Financial Group now owns 4,269 shares of the company's stock worth $1,104,000 after buying an additional 37 shares in the last quarter. Silver Coast Investments LLC grew its holdings in Johnson & Johnson by 3.8% during the 2nd quarter. Silver Coast Investments LLC now owns 1,066 shares of the company's stock worth $271,000 after acquiring an additional 39 shares during the last quarter. Townsend Asset Management Corp NC ADV increased its position in Johnson & Johnson by 0.6% in the 2nd quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company's stock valued at $1,630,000 after acquiring an additional 39 shares in the last quarter. Triumph Capital Management increased its position in Johnson & Johnson by 1.6% in the 2nd quarter. Triumph Capital Management now owns 2,531 shares of the company's stock valued at $643,000 after acquiring an additional 39 shares in the last quarter. Finally, Kwmg LLC raised its stake in shares of Johnson & Johnson by 1.7% in the third quarter. Kwmg LLC now owns 2,383 shares of the company's stock worth $631,000 after acquiring an additional 39 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Johnson Rice downgraded Johnson & Johnson from a "buy" rating to a "hold" rating in a report on Wednesday, October 21st. Weiss Ratings downgraded Johnson & Johnson from a "buy (b+)" rating to a "buy (b-)" rating in a research report on Friday, October 23rd. Morgan Stanley dropped their target price on Johnson & Johnson from $294.00 to $292.00 and set an "overweight" rating for the company in a research report on Thursday, October 15th. Guggenheim reaffirmed a "buy" rating and set a $287.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 7th. Finally, Wall Street Zen cut Johnson & Johnson from a "buy" rating to a "hold" rating in a report on Saturday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus price target of $276.54.

Read Our Latest Stock Report on Johnson & Johnson

Top Johnson & Johnson Stories

These are some of the JNJ stories that stood out recently:

  • Positive Sentiment: Phase 4 results for TREMFYA in axial psoriatic arthritis met key endpoints, with significant symptom improvement and more than twice the placebo reduction in MRI-assessed inflammation. The data could strengthen the drug’s commercial prospects. Article
  • Positive Sentiment: J&J announced the first U.S. commercial installation of its OTTAVA surgical robot at a Houston hospital, an early step in bringing the platform to market and expanding its surgical-technology business. Article
  • Positive Sentiment: The company submitted an FDA application to expand CAPLYTA’s use to bipolar I mania or mixed episodes, supported by two positive Phase 3 studies. Approval is not guaranteed, but another indication could broaden the drug’s growth potential. Article

Johnson & Johnson Price Performance

JNJ opened at $270.54 on Friday. The company has a fifty day moving average price of $267.53 and a two-hundred day moving average price of $250.98. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. Johnson & Johnson has a 52 week low of $199.90 and a 52 week high of $290.25. The firm has a market capitalization of $651.27 billion, a PE ratio of 40.99, a P/E/G ratio of 2.79 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating analysts' consensus estimates of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The company had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. During the same quarter in the prior year, the business posted $2.80 EPS. The firm's quarterly revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a yield of 2.0%. Johnson & Johnson's dividend payout ratio is presently 81.21%.

Insider Activity

In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of the firm's stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the transaction, the executive vice president owned 25,447 shares in the company, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Elizabeth Forminard sold 13,072 shares of the firm's stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $284.39, for a total value of $3,717,546.08. Following the transaction, the executive vice president owned 16,994 shares in the company, valued at approximately $4,832,923.66. This trade represents a 43.48% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.16% of the company's stock.

About Johnson & Johnson

(Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Featured Articles

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Johnson & Johnson Right Now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines